A UK COST-UTILITY ANALYSIS OF PACLITAXEL ALBUMIN COMPARED TO SOLVENT-BASED PACLITAXEL MONOTHERAPY AND DOCETAXEL MONOTHERAPY FOR PRETREATED METASTATIC BREAST CANCER (MBC)

被引：4
|
作者：
McLeod, E. J. [1 ]
Lloyd, A. [1 ]
Samyshkin, Y. [1 ]
Prunieras, F. [2 ]
Canney, P. [3 ]
机构：
[1] IMS Hlth, London, England
[2] ABRAXIS BIOSCI, Paris, France
[3] Beatson W Scotland Canc Ctr, Glasgow, Lanark, Scotland
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)71991-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A269 / A269
页数：1
相关论文
共 50 条
  • [41] UK cost-effectiveness analyses of docetaxel versus generic paclitaxel once weekly and nab-paclitaxel in patients with locally advanced or metastatic breast cancer (MBC) progressed after anthracycline chemotherapy
    Benedict, A.
    Cameron, D.
    Corson, H.
    Jones, S.
    VALUE IN HEALTH, 2007, 10 (06) : A336 - A336
  • [42] An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study
    Lazzaro, Carlo
    Bordonaro, Roberto
    Cognetti, Francesco
    Fabi, Alessandra
    De Placido, Sabino
    Arpino, Grazia
    Marchetti, Paolo
    Botticelli, Andrea
    Pronzato, Paolo
    Martelli, Elisa
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2013, 5 : 125 - 135
  • [43] Cost-effectiveness of nanoparticle albumin-bound paclitaxel versus docetaxel in the treatment of metastatic breast cancer.
    Gradishar, W
    Vishalpura, T
    Franklin, M
    Bramley, T
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S220 - S221
  • [44] ADVERSE EVENTS AND HOSPITALIZATIONS AMONG METASTATIC BREAST CANCER PATIENTS INITIATING SOLVENT BASED (SB)-PACLITAXEL OR ALBUMIN BOUND (NAB)-PACLITAXEL
    Bonafede, M. M.
    Cai, Q.
    Princic, N.
    Tran, O., V
    Parisi, M.
    VALUE IN HEALTH, 2016, 19 (03) : A133 - A134
  • [45] A COST-UTILITY ANALYSIS OF NAB-PACLITAXEL (ABRAXANE) PLUS GEMCITABINE IN METASTATIC PANCREATIC CANCER IN SLOVAK REPUBLIC
    Stetka, R.
    Ondrusova, M.
    Psenkova, M.
    Pastorek, T.
    Salek, T.
    VALUE IN HEALTH, 2015, 18 (07) : A464 - A464
  • [46] Overall survival analysis of a randomized phase III trial comparing nab-paclitaxel with solvent-based paclitaxel in patients with metastatic breast cancer previously treated with anthracycline
    Davidson, N.
    Tjulandin, S.
    O'Shaughnessy, J.
    Bhar, P.
    Gradishar, W.
    EJC SUPPLEMENTS, 2008, 6 (07): : 218 - 218
  • [47] Nanoparticle Albumin-Bound Paclitaxel and Solvent-Based Paclitaxel as Chemotherapy Options for Patients With Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
    Gangannapalle, Mahesh
    Shahnoor, Husna
    Sattar, Lubna
    Nagi, Talwinder K.
    Al-Tekreeti, Marwah
    Khan, Muhammad Waqas
    Haseeb, Madiha D.
    Khan, Areeba
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (07)
  • [48] COST EFFECTIVENESS ANALYSIS IN THE VENETO REGION OF NAB-PACLITAXEL MONOTHERAPY II LINE VERSUS CONVENTIONAL PACLITAXEL IN PATIENTS WITH BREAST CANCER AND FOR WHOM ANTHRACYCLINES ARE NOT INDICATED
    Maran, P. R.
    Aiello, A.
    Magri, M. R.
    Alberti, C.
    Visentin, E.
    Venturini, F.
    Scroccaro, G.
    VALUE IN HEALTH, 2012, 15 (07) : A423 - A423
  • [49] Salvage treatment with biweekly administration of paclitaxel (P) and gemcitabine (G) in patients (pts) with metastatic breast cancer (MBC) heavily pretreated with anthracycline and docetaxel containing regimens.
    Alexopoulos, A
    Karamouzis, MV
    Ioannidis, G
    Stavrinides, H
    Ardavanis, A
    Stavrakakis, J
    Georganta, C
    Kandilis, K
    Rigatos, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 86S - 86S
  • [50] Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation
    Vu, T.
    Ellard, S.
    Speers, C. H.
    Taylor, S. C. M.
    de Lemos, M. L.
    Hu, F.
    Kuik, K.
    Olivotto, I. A.
    ANNALS OF ONCOLOGY, 2008, 19 (03) : 461 - 464
12345